MX2016007066A - Identificacion de marcadores biologicos predictivos asociados con inhibidores de la via de wnt. - Google Patents

Identificacion de marcadores biologicos predictivos asociados con inhibidores de la via de wnt.

Info

Publication number
MX2016007066A
MX2016007066A MX2016007066A MX2016007066A MX2016007066A MX 2016007066 A MX2016007066 A MX 2016007066A MX 2016007066 A MX2016007066 A MX 2016007066A MX 2016007066 A MX2016007066 A MX 2016007066A MX 2016007066 A MX2016007066 A MX 2016007066A
Authority
MX
Mexico
Prior art keywords
wnt pathway
identification
pathway inhibitors
biomarkers associated
predictive biomarkers
Prior art date
Application number
MX2016007066A
Other languages
English (en)
Spanish (es)
Inventor
M Kapoun Ann
Zhang Chun
Original Assignee
Oncomed Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncomed Pharm Inc filed Critical Oncomed Pharm Inc
Publication of MX2016007066A publication Critical patent/MX2016007066A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2016007066A 2013-12-02 2014-12-02 Identificacion de marcadores biologicos predictivos asociados con inhibidores de la via de wnt. MX2016007066A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361910663P 2013-12-02 2013-12-02
US201461975339P 2014-04-04 2014-04-04
PCT/US2014/068097 WO2015084808A1 (en) 2013-12-02 2014-12-02 Identification of predictive biomarkers associated with wnt pathway inhibitors

Publications (1)

Publication Number Publication Date
MX2016007066A true MX2016007066A (es) 2016-09-08

Family

ID=53274023

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016007066A MX2016007066A (es) 2013-12-02 2014-12-02 Identificacion de marcadores biologicos predictivos asociados con inhibidores de la via de wnt.

Country Status (9)

Country Link
EP (1) EP3077546A4 (enExample)
JP (1) JP2017501137A (enExample)
CN (1) CN105829547A (enExample)
AU (1) AU2014357354A1 (enExample)
CA (1) CA2931975A1 (enExample)
HK (1) HK1223657A1 (enExample)
MX (1) MX2016007066A (enExample)
TW (1) TW201610168A (enExample)
WO (1) WO2015084808A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
HK1211887A1 (en) 2013-02-04 2016-06-03 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a wnt pathway inhibitor
US20180223372A1 (en) * 2015-08-03 2018-08-09 Oncomed Pharmaceutical, Inc. Identification of predictive biomarkers associated with wnt pathway inhibitors
WO2017048322A1 (en) * 2015-09-16 2017-03-23 Tobira Therapeutics, Inc. Cenicriviroc combination therapy for the treatment of fibrosis
JP7374765B2 (ja) 2016-10-26 2023-11-07 リープ セラピューティクス,インコーポレイテッド 抗dkk-1抗体を使用して癌を治療するためのバイオマーカーとしてのベータ-カテニンの使用
CN106990245B (zh) * 2017-04-05 2018-07-31 东南大学 检测pitx1表达量的试剂在制备胃癌预后评估试剂盒中的应用
CN110835372B (zh) * 2019-11-06 2020-12-01 上海健康医学院 一种靶向Frizzled7单克隆抗体及其制备方法与应用
JP7593584B2 (ja) * 2020-03-10 2024-12-03 学校法人杏林学園 腫瘍細胞マーカー、および腫瘍細胞を検出または回収する方法
CN111735949B (zh) * 2020-07-17 2023-07-21 北京信诺卫康科技有限公司 Wnt7a和CA125联合用作早期卵巢癌生物标志物以及试剂盒
CN115337400A (zh) * 2021-05-13 2022-11-15 中国科学院分子细胞科学卓越创新中心 诊断和治疗肿瘤的试剂及其用途
CN113293212A (zh) * 2021-06-17 2021-08-24 深圳华因康基因科技有限公司 一种检测神经母细胞瘤复发转移基因fzd2扩增的引物探针及其应用
JPWO2023113013A1 (enExample) * 2021-12-17 2023-06-22
WO2024189200A1 (en) * 2023-03-15 2024-09-19 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Cancer stratification and treatment

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681718A (en) 1986-03-14 1997-10-28 Celltech Limited Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DE69127627T2 (de) 1990-08-29 1998-02-19 Genpharm Int Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
AU6069300A (en) * 1999-07-02 2001-01-22 Chiron Corporation Novel human genes and gene expression products
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
WO2002060919A2 (en) 2000-12-12 2002-08-08 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
EP1549144A4 (en) * 2002-10-04 2010-01-06 Univ California METHOD FOR THE TREATMENT OF CANCER BY INHIBITION OF THE WNT SIGNALING LINE
US7365168B2 (en) 2002-10-15 2008-04-29 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP2385069A3 (en) 2003-11-12 2012-05-30 Biogen Idec MA Inc. Neonatal Fc rReceptor (FcRn)- binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
WO2005075514A2 (en) 2004-03-10 2005-08-18 Lonza Ltd. Method for producing antibodies
CA2581208A1 (en) 2004-08-30 2006-03-09 Lonza Biologics Plc. Affinity- plus ion exchange- chromatography for purifying antibodies
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
JP5129149B2 (ja) 2005-10-31 2013-01-23 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 癌を処置および診断するための組成物および方法
WO2008031009A2 (en) 2006-09-08 2008-03-13 Genentech, Inc. Wnt antagonists and their use in the diagnosis and treatment of wnt-mediated disorders
WO2008039071A2 (en) * 2006-09-29 2008-04-03 Agendia B.V. High-throughput diagnostic testing using arrays
PL2066694T3 (pl) 2006-09-29 2016-04-29 Oncomed Pharm Inc Kompozycje i sposoby diagnozowania i leczenia nowotworu
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
EP2275431A3 (en) 2008-01-18 2011-05-25 Bio-Rad Laboratories, Inc. Enhanced fractionation of phosphorylated and nonphosphorylated biomolecules by apatite chromotography
TWI506037B (zh) 2008-09-26 2015-11-01 Oncomed Pharm Inc 捲曲結合劑類及彼等之用途
US20100169025A1 (en) * 2008-10-10 2010-07-01 Arthur William T Methods and gene expression signature for wnt/b-catenin signaling pathway
US20120053079A1 (en) * 2009-03-06 2012-03-01 University Of South Alabama Methods and compositions for the diagnosis, prognosis and treatment of cancer
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Wnt拮抗劑及治療和篩選方法
AU2011205409B2 (en) 2010-01-12 2015-08-20 Oncomed Pharmaceuticals, Inc. Wnt-binding agents and uses thereof
WO2013086260A2 (en) * 2011-12-09 2013-06-13 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of cancer

Also Published As

Publication number Publication date
EP3077546A1 (en) 2016-10-12
CA2931975A1 (en) 2015-06-11
EP3077546A4 (en) 2017-04-26
WO2015084808A4 (en) 2015-08-13
WO2015084808A1 (en) 2015-06-11
CN105829547A (zh) 2016-08-03
JP2017501137A (ja) 2017-01-12
HK1223657A1 (zh) 2017-08-04
AU2014357354A1 (en) 2016-06-09
TW201610168A (zh) 2016-03-16

Similar Documents

Publication Publication Date Title
MX2016007066A (es) Identificacion de marcadores biologicos predictivos asociados con inhibidores de la via de wnt.
IL261353A (en) idh1 suppressors for the treatment of hematological malignancies and solid tumors
LT3198033T (lt) Fgfr mutantinių genų rinkinių panaudojimas identifikuojant vėžiu sergančius pacientus, kurie reaguos į gydymą fgfr inhibitoriumi
MX2017004037A (es) Derivados de acido boronico.
MX372823B (es) Derivados de ácido borónico.
MX383296B (es) Vigilancia del tratamiento y pronóstico de los trastornos de la proliferación utilizando inhibidores de la vía de hedgehog.
EP3414692A4 (en) HIGH-RATE IDENTIFICATION OF PATIENT-SPECIFIC NEOEPITOPES AS THERAPEUTIC TARGETS FOR CANCER IMMUNOTHERAPIES
CL2016001082A1 (es) Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa
EP3119908A4 (en) Determining cancer aggressiveness, prognosis and responsiveness to treatment
MX370336B (es) Derivados de acido boronico.
HK1231513A1 (zh) 活化素抑制劑應答預測和用於治療的用途
MX2012009030A (es) Identificacion de mutacion lkb1 como biomarcador predictivo para sensibilidad a inhibidores de tor cinasa.
MX2016002423A (es) Composiciones y metodos de diagnostico para el tratamiento de glioblastoma.
EA201690007A1 (ru) Соединения, ингибирующие металлоферменты
MX2020000386A (es) Inhibidores heterociclicos de la cinasa atr.
MX2018006781A (es) Inhibidores de mat2a para el tratamiento del cancer que no expresen mtap.
MX2014011500A (es) Diagnosticos y tratamientos relacionados a inhibidores her3.
EA201591278A1 (ru) Композиции, содержащие c1-inh, и способы профилактики и лечения расстройств, ассоциированых с дефицитом ингибитора с1 эстеразы
EA201491701A1 (ru) Лечение рака ингибиторами tor киназы
MX375716B (es) Método para tratar adenocarcinoma de pulmón.
MX2015011428A (es) Metodos para tratar y prevenir la resistencia a los farmacos para el cancer.
MY180834A (en) Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
WO2014205266A3 (en) Compositions and methods for detecting and treating glioblastoma
EP4513187A3 (en) Methods of detecting prostate cancer
GB201413162D0 (en) Prediction of cancer treatment based on determination of enzymes or metabolites of the kynurenine pathway